TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35323895

Group type: EXPERIMENTAL
Intervention: Group B Streptococcus early-onset disease (GBS EOD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B Streptococcus late-onset disease (GBS LOD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninfected infants
Number of subjects: 0
Study: 35323905

Group type: EXPERIMENTAL
Intervention: 10 mg oral dydrogesterone (DYD) ter-in-die (tid) for luteal support
Number of subjects: 217
Study: 35323932

Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing soluble urokinase plasminogen activator receptor (suPAR)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing interleukin 6 (IL-6)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Clinical parameters alone (without biomarkers)
Number of subjects: 426
Study: 35324081

Group type: EXPERIMENTAL
Intervention: PrEP adherence (≥80% adherence)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PrEP adherence (<80% adherence)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PrEP uptake
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PrEP effectiveness confidence
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Couple-level dynamics
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Community-level support
Number of subjects: 37
Study: 35324095

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antipsychotic treatment)
Number of subjects: 0
Study: 35324429

Group type: EXPERIMENTAL
Intervention: ASE algorithm for assessing MR severity
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Post mitral intervention LV reverse remodeling
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Severe MR by CMR
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Definitely severe MR by ASE algorithm
Number of subjects: 152
Study: 35324532

Group type: EXPERIMENTAL
Intervention: selpercatinib plus crizotinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: bevacizumab combined with pemetrexed and carboplatin
Number of subjects: 1
Study: 35324894

Group type: COMPARATOR
Intervention: Total artificial sweeteners (above median exposure in consumers)
Number of subjects: 102865

Group type: COMPARATOR
Intervention: Aspartame
Number of subjects: 102865

Group type: COMPARATOR
Intervention: Acesulfame-K
Number of subjects: 102865

Group type: COMPARATOR
Intervention: Total artificial sweeteners
Number of subjects: 102865
Study: 35325189

Group type: EXPERIMENTAL
Intervention: Combined or separate measures of food reward or biometric responses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Naïve model (linear model including only an intercept)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Energy intake from an ad libitum buffet of 8 foods
Number of subjects: 100
Study: 35325195

Group type: EXPERIMENTAL
Intervention: Organic semi-conducting (OSC) sensors
Number of subjects: 3921

Group type: EXPERIMENTAL
Intervention: Trained dogs
Number of subjects: 3921

Group type: EXPERIMENTAL
Intervention: Dog screening plus confirmatory PCR test
Number of subjects: 3921
Study: 35325211

Group type: EXPERIMENTAL
Intervention: JNJ-74699157 (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: JNJ-74699157 (200 mg)
Number of subjects: 10
Study: 35325225

Group type: EXPERIMENTAL
Intervention: Lenvatinib (MTD 24 mg) with capecitabine-based chemoradiation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood-based protein biomarkers (TSP-2, VEGF-R3, VEGF)
Number of subjects: 20
Study: 35326718

Group type: EXPERIMENTAL
Intervention: TTFields/sorafenib (150 kHz for ≥18 h/day with sorafenib 400 mg BID)
Number of subjects: 27
Study: 35327522

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 538
Study: 35327546

Group type: EXPERIMENTAL
Intervention: Acylcarnitine levels in patients with acute coronary syndrome
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: C5 levels in unstable angina
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: C10, C16, C18:1 and C18:2 levels in stable angina
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: C2, C3, C4 and C8 levels in patients with diabetes mellitus
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: C2, C4, C5 and C6 levels in patients with heavier calcification and lower left ventricular ejection fraction (LVEF)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: C4 and C5 levels in high CAD complexity group (SYNTAX Score > 22)
Number of subjects: 958
Study: 35327768

Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation targets
Number of subjects: 0
Study: 35328299

Group type: EXPERIMENTAL
Intervention: Handheld diagnostic devices (tympanic thermometer, pulse oximeter, hemoglobinometer, glucometer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse oximeter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Handheld diagnostic devices
Number of subjects: 0
Study: 35328847

Group type: EXPERIMENTAL
Intervention: Flu SensDx device testing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Influenza vaccination
Number of subjects: 150
Study: 35329987

Group type: EXPERIMENTAL
Intervention: Anterior segment optical coherence tomography angiography (AS-OCTA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: AS-OCTA
Number of subjects: 46
Study: 35330570

Group type: EXPERIMENTAL
Intervention: Short-message notifications
Number of subjects: 0
Study: 35330925

Group type: EXPERIMENTAL
Intervention: Fluid volume reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluid, electrolyte, energy and nitrogen intake, fluid loss, estimated glomerular filtration rate (eGFR), and estimated plasma osmolality (eOSM) measurements
Number of subjects: 0
Study: 35331039

Group type: EXPERIMENTAL
Intervention: Nonpharmacological health-related behaviors adherence
Number of subjects: 0
Study: 35331304

Group type: EXPERIMENTAL
Intervention: Prehospital POCUS with remote real-time supervision
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remote real-time supervision
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Technical feasibility and quality of communication and live stream
Number of subjects: 24
Study: 35331323

Group type: EXPERIMENTAL
Intervention: Nasal pressure swings measurement during non-invasive respiratory support (NRS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Esophageal pressure swings measurement
Number of subjects: 61
Study: 35331335

Group type: EXPERIMENTAL
Intervention: ITNK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-ITNK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sgBCL11B T cells
Number of subjects: 0
Study: 35331419

Group type: EXPERIMENTAL
Intervention: Resmetirom (MGL-3196)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35331503

Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual nutrition
Number of subjects: 120
Study: 35331504

Group type: EXPERIMENTAL
Intervention: Nutrition-focused quality improvement program (QIP) including education on macro- and micronutrient intake and physical exercise, dietary counseling, and provision of oral nutritional supplements (ONS) for daily intake over 60 days.
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Nutrition-focused quality improvement program (QIP)
Number of subjects: 677
Study: 35331634

Group type: EXPERIMENTAL
Intervention: Vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks
Number of subjects: 8
Study: 35331637

Group type: EXPERIMENTAL
Intervention: iVAC2L mechanical circulatory support (MCS)
Number of subjects: 29
Study: 35332036

Group type: EXPERIMENTAL
Intervention: High-dose radiation (radiosurgery) targeting the retroperitoneal coeliac plexus nerve bundle with a single fraction of 25 Gy
Number of subjects: 120
Study: 35332048

Group type: EXPERIMENTAL
Intervention: AFCA
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: AAD
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: Repeat procedure after AAD use
Number of subjects: 2999
Study: 35332134

Group type: EXPERIMENTAL
Intervention: Antidepressant (escitalopram 20 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Antidepressant plus COX-2 inhibitor (celecoxib)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis for IL-1β
Number of subjects: 66
Study: 35332278

Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) therapy, median 4.0 cycles (range, 1-20)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) therapy
Number of subjects: 248
Study: 35332289

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 29
Study: 35332298

Group type: EXPERIMENTAL
Intervention: Complement blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35332334

Group type: EXPERIMENTAL
Intervention: Two doses of COVID-19 vaccine
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Three doses of COVID-19 vaccine
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Third dose of COVID-19 vaccine
Number of subjects: 457

Group type: COMPARATOR
Intervention: Full vaccination (two doses)
Number of subjects: 457
Study: 35332426

Group type: EXPERIMENTAL
Intervention: Standard intraventricular ICP monitoring
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noninvasive ICP monitor (ICPni)
Number of subjects: 18
Study: 35333095

Group type: EXPERIMENTAL
Intervention: High-frequency, low-tidal-volume mechanical ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ventilation (control group not explicitly mentioned)
Number of subjects: 0
Study: 35333110

Group type: EXPERIMENTAL
Intervention: AAVhu68 delivered to the cerebrospinal fluid (CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAVrh10 or AAV9 (systemic or CSF administration)
Number of subjects: 0
Study: 35333135

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35333737

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 29
Study: 35333839

Group type: EXPERIMENTAL
Intervention: CT LUCIA 611P intraocular lens (IOL)
Number of subjects: 339
Study: 35333947

Group type: EXPERIMENTAL
Intervention: IUGR group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 35334038

Group type: EXPERIMENTAL
Intervention: CS-VR-Onco (Core Set for Vocational Rehabilitation for Cancer Survivors)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CS-VR-Onco
Number of subjects: 28
Study: 35334334

Group type: EXPERIMENTAL
Intervention: High Tibial Osteotomy (HTO)
Number of subjects: 4
Study: 35337339

Group type: EXPERIMENTAL
Intervention: Combination of famitinib (angiogenesis inhibitor), camrelizumab (PD-1 monoclonal antibody), and chemotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of famitinib, camrelizumab, and chemotherapy
Number of subjects: 48
Study: 35337335

Group type: EXPERIMENTAL
Intervention: Visually guided target walking (TW) with handrail support
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal treadmill walking (NW)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mean CoM Euclidean distance TW-NW
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CoM trajectory length during TW
Number of subjects: 13
Study: 35337365

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study: 35337388

Group type: EXPERIMENTAL
Intervention: Multimodal physical therapy program (manual therapy, therapeutic exercise, static progressive splinting) over 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manipulation under anesthesia followed by physical therapy
Number of subjects: 10
Study: 35337614

Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Tubal ligation or no surgery
Number of subjects: 1200
Study: 35337750

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP) using archival tumor tissue
Number of subjects: 39

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 39
Study: 35337972

Group type: EXPERIMENTAL
Intervention: Abemaciclib + Endocrine Therapy (ET)
Number of subjects: 5591

Group type: COMPARATOR
Intervention: Endocrine Therapy (ET) alone
Number of subjects: 5591
Study: 35338084

Group type: EXPERIMENTAL
Intervention: VCN-01
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VCN-01 + nab-paclitaxel + gemcitabine
Number of subjects: 28
Study: 35338252

Group type: EXPERIMENTAL
Intervention: Maximal weight loss (MWL) between 5% to 15%
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Average total fluid administration (TFA) > 150 mL/kg birthweight/day
Number of subjects: 883
Study: 35338445

Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction (PCR)
Number of subjects: 48
Study: 35338773

Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T cell-based therapy
Number of subjects: 48
Study: 35339025

Group type: EXPERIMENTAL
Intervention: Ribavirin 400 mg BID for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ribavirin 1400 mg BID in 28-day cycles (continuously dosed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 20
Study: 35339285

Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP 40 to 130 mmHg
Number of subjects: 12169

Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP 130 to 180 mmHg
Number of subjects: 12169

Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP above 180 mmHg
Number of subjects: 12169

Group type: EXPERIMENTAL
Intervention: Nonmortality outcomes (hospital length of stay, ICU length of stay, discharge to skilled nursing/inpatient rehabilitation, hospital charges)
Number of subjects: 12169
Study: 35339664

Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: TyG index combined with GGT
Number of subjects: 238
Study: 35339766

Group type: EXPERIMENTAL
Intervention: Healthy Summer Learners (HSL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 21st Century Summer Learning Program (21 C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 35340081

Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metastasectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapies for metastatic lesions
Number of subjects: 0
Study: 35340264

Group type: EXPERIMENTAL
Intervention: Taxanes + PFT (platin-5FU + trastuzumab)
Number of subjects: 65

Group type: COMPARATOR
Intervention: PFT (platin-5FU + trastuzumab)
Number of subjects: 65
Study: 35340685

Group type: EXPERIMENTAL
Intervention: Surgery or local excision at 13-16 weeks (experimental arm)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Surgery or local excision at 9-11 weeks (control arm)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: nCRT with a total dose of 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus 45 Gy in 25 fractions on the whole pelvis, with continuous oral capecitabine chemotherapy.
Number of subjects: 148
Study: 35341327

Group type: EXPERIMENTAL
Intervention: Coronary and cardiac imaging (invasive or computed tomography angiography, magnetic resonance or echocardiography)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coronary and cardiac imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evidence-based treatments
Number of subjects: 100
Study: 35341613

Group type: EXPERIMENTAL
Intervention: Medication for addiction treatment (MAT)
Number of subjects: 28
Study: 35341612

Group type: EXPERIMENTAL
Intervention: Communication training intervention
Number of subjects: 1026
Study: 35341724

Group type: EXPERIMENTAL
Intervention: Radial wave therapy (RW group) - 6 weekly sessions
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham therapy (control group) - 6 weekly sessions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radial wave therapy (RW group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 80
Study: 35341952

Group type: EXPERIMENTAL
Intervention: Rectal expulsion device (RED)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Normal RED
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Abnormal RED (expulsion within 5 seconds or >120 seconds)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Seated RED retained >13 seconds
Number of subjects: 52
Study: 35341993

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 75
Study: 35342110

Group type: EXPERIMENTAL
Intervention: Infection prevention protocols implemented in homes via community health workers/Promotoras.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPSAC involvement in trial oversight and shared decision-making.
Number of subjects: 0
Study: 35342321

Group type: EXPERIMENTAL
Intervention: E-GPS (Glasgow prognostic score after first-line chemotherapy)
Number of subjects: 138

Group type: COMPARATOR
Intervention: B-GPS (Glasgow prognostic score at baseline)
Number of subjects: 138
Study: 35342457

Group type: EXPERIMENTAL
Intervention: Oral infigratinib (dose-escalation, dose-finding, and dose-expansion phases)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral infigratinib (specific dose to be confirmed in dose-expansion phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (baseline data collection in PROPEL)
Number of subjects: 0
Study: 35342822

Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 or 2.0 mg) monthly or as-needed (PRN) for 24 months
Number of subjects: 1097
Study: 35342978

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg QD
Number of subjects: 0
Study: 35343066

Group type: EXPERIMENTAL
Intervention: WTC RRWV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated unexposed cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mineral dust work exposure
Number of subjects: 0
Study: 35343187

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg for six cycles or until disease progression or unacceptable toxicity or withdrawal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg
Number of subjects: 60
Study: 35343188

Group type: EXPERIMENTAL
Intervention: Plasma testing for EGFR mutation analysis
Number of subjects: 245

Group type: COMPARATOR
Intervention: Tissue sample testing for EGFR mutation analysis
Number of subjects: 245
Study: 35343323

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant photon or proton radiotherapy
Number of subjects: 25
Study: 35343768

Group type: EXPERIMENTAL
Intervention: Diet intervention; specific details not provided
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metagenomics approach; specific details not provided
Number of subjects: 0
Study: 35343910

Group type: EXPERIMENTAL
Intervention: PEAR-004, a smartphone-based investigational digital therapeutic, added to standard treatments for schizophrenia.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sham control (nonspecific digital sham control).
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: PEAR-004, a smartphone-based investigational digital therapeutic.
Number of subjects: 112
Study: 35344040

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax combined with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venetoclax as a monotherapy
Number of subjects: 0
Study: 35344082

Group type: EXPERIMENTAL
Intervention: Breech presentation
Number of subjects: 507

Group type: COMPARATOR
Intervention: Cephalic presentation
Number of subjects: 507
Study: 35344210

Group type: EXPERIMENTAL
Intervention: Eryaspase (150 u/kg)
Number of subjects: 55
Study: 35344274

Group type: EXPERIMENTAL
Intervention: PillarX device (bimodular microfluidic device)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pillar-device and X-magnetic device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PillarX device
Number of subjects: 0
Study: 35344570

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) assessment of quadriceps rectus femoris and diaphragm muscles using Shear-Wave Elastography (SWE)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) assessment of diaphragm and rectus femoris muscles
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined model of one diaphragm US marker and one limb muscle US marker
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Medical Research Council (MRC) sum score for muscle testing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Airway occlusion pressure (P0.1)
Number of subjects: 84
Study: 35344588

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran etexilate (P-gp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin (BCRP and OAT3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin (OCT2 and MATE1/2K)
Number of subjects: 0
Study: 35344689

Group type: EXPERIMENTAL
Intervention: Mass spectrometry screening for monoclonal gammopathies
Number of subjects: 7622

Group type: COMPARATOR
Intervention: Serum protein electrophoresis with immunofixation electrophoresis
Number of subjects: 7622

Group type: EXPERIMENTAL
Intervention: Mass spectrometry screening
Number of subjects: 7622

Group type: EXPERIMENTAL
Intervention: Screen-detected monoclonal gammopathies
Number of subjects: 7622

Group type: EXPERIMENTAL
Intervention: All monoclonal gammopathies
Number of subjects: 7622
Study: 35345247

Group type: EXPERIMENTAL
Intervention: CONFIRM high-risk model (CHM)
Number of subjects: 5936

Group type: EXPERIMENTAL
Intervention: PROMISE high-risk model (PHM)
Number of subjects: 5936

Group type: COMPARATOR
Intervention: Comparison of CHM and PHM
Number of subjects: 5936
Study: 35345248

Group type: EXPERIMENTAL
Intervention: Potent P2Y12 inhibitors
Number of subjects: 344

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: DAPT (dual antiplatelet therapy)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: History of CVD
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: PCI treatment
Number of subjects: 344